Related Experiment Video

Updated: Jun 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy

Cesare Gridelli1, Antonio Rossi, Paolo Maione

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. cgridelli@libero.it

The Oncologist
|September 4, 2009
PubMed

Insights

Lung cancer vaccine therapy is re-emerging as a promising approach for non-small cell lung cancer (NSCLC). Ongoing trials focus on advanced NSCLC stages, particularly in adjuvant and locally advanced settings, showing potential for improved outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccinology

Background:

  • Non-small cell lung cancer (NSCLC) is the leading cause of cancer death globally, with current treatments reaching effectiveness plateaus.
  • Despite extensive research, no specific active cancer vaccine has been approved for NSCLC therapy.
  • Vaccine therapy is re-emerging as a potential therapeutic strategy for NSCLC.

Purpose of the Study:

  • To review clinical trials of various cancer vaccines in early and advanced stage NSCLC.
  • To focus on vaccines in advanced stages of development and their potential impact.

Main Methods:

  • Review of clinical trials involving different cancer vaccines for NSCLC.
  • Focus on trials in early, advanced, adjuvant, and locally advanced disease settings.
  • Highlighting ongoing Phase III randomized trials for specific vaccines.

Main Results:

  • Vaccine therapies have shown promise in NSCLC, particularly in adjuvant and locally advanced settings.
  • Ongoing Phase III trials are evaluating melanoma-associated antigen A3 and liposomal BLP25 vaccines.
  • New paradigms in combination therapy and clinical trial design are emerging.

Conclusions:

  • Cancer vaccine therapy represents a renewed therapeutic avenue for NSCLC.
  • Further research and clinical trials are crucial to establish the efficacy of vaccines in NSCLC treatment.
  • Combination approaches and refined trial designs may enhance vaccine effectiveness.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...